• Publications
  • Influence
Neuroblastoma: a disease requiring a multitude of imaging studies.
  • B. Kushner
  • Medicine
    Journal of nuclear medicine : official…
  • 1 July 2004
TLDR
Defining disease status requires CT (or MRI), bone scan, metaiodobenzylguanidine (MIBG) scan, bone marrow tests, and urine catecholamine measurements, allowing identification of patients who, despite a favorable clinical profile, are likely to develop lethal metastatic disease, versus patients who have an ominous clinical profile.
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.
TLDR
For control of DSRCT, the experience supports intensive use of HD-CAV, aggressive surgery to resect visible disease, radiotherapy to high-risk sites, and myeloablative chemotherapy with stem-cell rescue in selected cases.
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
TLDR
The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies, and has the potential to increase survival with better than expected quality of life.
Neuroblastoma metastatic to the central nervous system
TLDR
The authors hypothesized that, with improved survival from childhood metastatic neuroblastoma (NB), the incidence of CNS (intraparenchymal and leptomeningeal) spread may increase.
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
TLDR
The favorable outcome associated with FCGR2A (R/R) genotype is consistent with the proposed role of FC GR2A and phagocyte-mediated ADCC in 3F8 plus GM-CSF immunotherapy.
Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity.
TLDR
Optimal ADCC using human PMN, human solid tumor cells, and a clinically active MoAb (conditions that contrast with the heterologous antibodies and nonhuman or nonneoplastic targets used in most models of PMN ADCC) required CD11b, CD11c, FcRII, and the PI-linked F cRIII.
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
TLDR
Excellent antitumor efficacy and manageable toxicity support the dose-intensive use of HD-CAV for pPNET in children, as well as in young adults.
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
TLDR
Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs using high-dose, short-term chemotherapy.
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.
TLDR
3F8/GM-CSF is well tolerated and shows promise for treatment of minimal residual NB in BM, and side effects were limited to readily manageable pain and rash of short duration.
...
...